EMA Deciding If Donanemab For Alzheimer’s & Three Other Drugs Merit Fast-Tracking
Executive Summary
Eli Lilly, MSD, CLS and Pfizer could this week find out if the European Medicines Agency will agree that their planned EU marketing applications for donanemab, sotatercept, garadacimab and aztreonam-avibactam respectively deserve an accelerated assessment.